Pleural and ascites of lung cancer
Conditions
Interventions
2 groups:Cisplatin combined with bevacizumab vs contral
Sponsors
BenQ Hospital Affiliated to Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: A total of 86 patients with malignant pleural and ascites caused by lung cancer admitted to our hospital from June 2018 to September 2020 were selected. Histologically or pathologically diagnosed as a lung cancer patient with clinical stage IV or above, the pleural effusion was confirmed to be malignant pleural effusion by exfoliated cytology and ultrasonography; the expected survival time is> 3 months and 1 patient before enrollment Has not received chemotherapy, targeted therapy or other anti-tumor treatments for the first month; routine blood tests, liver function, renal function, and electrocardiogram examinations were performed before treatment, and there were no abnormalities; none of the patients had a history of allergy to biological agents
Exclusion criteria
Exclusion criteria: Received chemotherapy and targeted therapy within the past month; patients with severe cardiovascular and liver and kidney dysfunction; patients with allergic reactions to the drugs used in this study (cisplatin, bevacizumab, etc.); pregnant and lactating women .
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life score; | — |
Secondary
| Measure | Time frame |
|---|---|
| (Hypoxia inducible factor, HIF- 1a;Pleural fluid and ascites relief index; | — |
Countries
China
Contacts
Public ContactZhou Zhi
BenQ Hospital Affiliated to Nanjing Medical University
Outcome results
None listed